H.C. Wainwright raised the firm’s price target on Cabaletta Bio to $25 from $17 and keeps a Buy rating on the shares. The analyst revisited expectations for CABA-201 in lupus and other indications. The firm raised its peak sales estimate to $2.7B from $800M.
Meet Your ETF AI Analyst
- Discover how TipRanks' ETF AI Analyst can help you make smarter investment decisions
- Explore ETFs TipRanks' users love and see what insights the ETF AI Analyst reveals about the ones you follow.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
See the top stocks recommended by analysts >>
Read More on CABA:
- Cabaletta Bio Reports Third Quarter 2023 Financial Results and Provides Business Update
- Cabaletta Bio expects cash to fund operations into 4Q25
- Cabaletta Bio reports Q3 EPS (37c), consensus (40c)
- Cellares, Cabaletta Bio team to evaluate CABA-201 manufacturing on Cell Shuttle
- Cabaletta Bio receives FDA clearance of CABA-201 IND application